行情

ACIU

ACIU

AC Immune
NASDAQ

实时行情|Nasdaq Last Sale

9.45
+0.25
+2.72%
盘后: 9.45 0 0.00% 16:00 01/21 EST
开盘
9.12
昨收
9.20
最高
9.54
最低
9.11
成交量
10.61万
成交额
--
52周最高
11.55
52周最低
3.250
市值
6.38亿
市盈率(TTM)
12.82
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ACIU 新闻

  • 美国疾控中心证实美国第一例冠状病毒感染病例
  • 央视.3小时前
  • 波音预计监管机构在6月或7月之前不会批准737Max复飞
  • 新浪美股.3小时前
  • 美国疾控中心预计宣布新型冠状病毒在美首例感染案例
  • 央视.3小时前
  • 绿光资本坚持做空Netflix:趁其股价反弹进行了"投资"
  • 新浪美股.3小时前

更多

所属板块

生物技术和医学研究
-0.76%
制药与医学研究
-0.40%

热门股票

名称
价格
涨跌幅

ACIU 简况

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
展开

Webull提供AC Immune SA的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。